Bristol-myers Squibb Compnay

Gesellschaft Fur Biotechnologische Forschung Mbh

Soong-Hoon Kim

James A Johnson

Gregory D Vite

Robert Michael Borzilleri

Ji Jiang

Ashvinikumar V Gavai

Heather J Finlay

Brian E Fink

Yufen Zhao

George O Tora

Katerina Leftheris

Jennifer X Qiao

Wayne D Vaccaro

Rajeev S Bhide

Tammy C Wang

Charles Z Ding

Zulan Pi

John T Hunt

Libing Chen

Alicia Regueiro-Ren

John E Lloyd

Liqi He

Bingwei Vera Yang

Gerhard H&ouml;fle

Litai H Zhang

Ping Chen

R Michael Lawrence

David S Weinstein

Wei Meng

John L Gilmore

James Edward Sheppeck

Toomas Mitt

Claude A Quesnelle

Michael C Myers

Hannguang J Chao

Brandon Lee Parkhurst

Andrew James Nation

Monique Phillips

Ying Wang

Dharmpal S Dodd

Mark George Saulnier

Steven P Seitz

Wen-Ching Han

Jay A Markwalder

Xiao-Tao Chen

Francis Lee

Gang Wu

David R Tortolani

Gerhard Hoefle

Carol Hui Hu

Patrice Gill

Tram N Huynh

Wenying Li

Lidia M Doweyko

Jianxin Feng

Denis Favreau

Zhenrong Guo

Shankar Swaminathan

Thomas Leibold

Arthur M Doweyko

John E Thornton

Nicole Glaser

Joseph E Carpenter

Wen Sen Li

Kenneth J Leavitt

Claude Quesnelle

Ashvinikumar Gavai

Litai Zhang

The present invention provides compounds of Formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions. 

Multicyclic compounds as farnesoid X receptor modulators

The present invention provides compounds of Formula (I) wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments. 

4-hydroxy-3-sulfonylpyridin-2(1H)-ones as APJ receptor agonists

The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments. 

2,4-dihydroxy-nicotinamides as APJ agonists

The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.

4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists

The present invention provides compounds of Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used medicaments. 

Sulfone amide linked benzothiazole inhibitors of endothelial lipase

Disclosed are compounds of Formula (I): (Formula (I)) wherein: Ris &#x2014;CHCHCF; Ris &#x2014;CHCHCHF, &#x2014;CHCFCH, &#x2014;CHCHCF, &#x2014;CHCH(CH)CF, &#x2014;CHCHCFCH, (Formulae (II), (III), (IV), (V) or (VI): Ris H or &#x2014;CH; Ring A is phenyl or pyridinyl; and R, R, R, R, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer. 

Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds

The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazopyridazines inhibit protein kinase activity thereby making them useful as anticancer agents.

Imidazopyridazinecarbonitriles useful as kinase inhibitors

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicament.

Ketone linked benzothiazole inhibitors of endothelial lipase

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.

Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase

The present invention relates to compounds of the formula in which the variables G, W, Q, X, Y, B, B, Z, Z, and R-Rare as defined herein, methods for the preparation of the derivatives and intermediates thereof.

Epothilone derivatives

Disclosed are compounds of Formula (I) or prodrugs thereof; wherein: Ris &#x2014;CHCFor &#x2014;CHCHCF; Ris &#x2014;CHCF, &#x2014;CHCHCF, or &#x2014;CHCHCHCF; Ris H or &#x2014;CH; each Ris independently F, Cl, &#x2014;CN, &#x2014;OCH, and/or &#x2014;NHCHCHOCH; and z is zero, 1, or 2. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.

Bisfluoroalkyl-1,4-benzodiazepinone compounds

The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) pyrrolotriazines inhibit protein kinase activity thereby making them useful as anticancer agents. 

Substituted pyrrolotriazines as protein kinase inhibitors

Sulfonyl containing benzothiazole inhibitors of endothelial lipase

Growing community of inventors

Titusville, NJ, United States of America

Soong-Hoon Kim